Meta-analyses of clinical trials in patients with non-small cell lung cancer: Minireview

Neoplasma

Volumn 51, Issue 5, 2004, Pages 334-340

  Kovac V ^a   Smrdel, U ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Chemotherapy; Meta analysis; Non small cell lung cancer; Radiotherapy; Surgery

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; NEUTROPENIA; POSTOPERATIVE CARE; QUALITY OF LIFE; SHORT SURVEY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 8444229807     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (57)

1. ARRIAGADA R, BERGMAN B, DUNANT A, LE CHEVALIER T, PIGNON JP, VANSTEENKISTE J. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360.
2. ARRIAGADA R, LE CHEVALIER T, QUOIX E, RUFFIE P, DE CREMOUX H et al. ASTRO Plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. Int J Radiat Oncol Biol Phys 1991; 20: 1183-1190.
3. BAGGSTROM MQ, SOCINSKI MA, HENSING TA, POOLE C. Addressing the optimal number of cytotoxic agents in stage III/ IV non-small cell lung cancer (NSCLC): A meta-analysis of the published literature [abstract]. 39th Annual Meeting of the ASCO. May 32-June 3, 2003, Chicago, Illinois. Meeting Proceeding 2003; 22: 624.
4. BAILAR III JC. The promise and problems of meta-analyses editorial. N Engl J Med 1997; 337: 559-561.
5. BONOMI P, KIM K, FAIRCLOUGH D, CELLA D, KUGLER J et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18: 623-631.
6. BOTA S, AULIAC JB, PARIS C, METAYER J, SESBOUE R et al. Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy. Am J Respir Crit Care Med 2001; 164: 1688-1693.
7. BUENO R, RICHARDS WG, SWANSON SJ, JAKLITSCH MT, LUKANICH JM et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000; 70: 1826-1831.
8. BURDETT S, PARMAR MKB, STEWARD LA, SOUHAMI RL, ARRIAGADA R et al, for PORT Meta-analysis Trialists Group. Post-operative radiotherapy in non-small cell lung cancer: a systematic meta-analysis using individual data from 9 randomised controlled trials. Lancet 1998; 352: 257-263.
9. CANCER REGISTRY OF SLOVENIA. Cancer incidence in Slovenia 2000. Report No. 42. Ljubljana: Institute of Oncology, 2003.
10. CURRAN WJ JR, SCOTT C, LANGER C, KOMAKI R, LEE J et al. Phase III comparison of sequential vs concurrent chemoradiation fo patients with unresected stage III non-small cell lung cancer: initial report of Radiation Therapy Oncology Group. 36th Annual Meeting of ASCO. May 20-23, 200, New Orleans, Lousiana. Program/Proceeding 2000; 19: 484a.
11. DEBEVEC M, BITENC M, VIDMAR S, ROTT T, OREL J et al. Postoperative radiotherapy for radically resected N2 non-small-cell lung cancer (NCSLC): randomised clinical study 1988-1992. Lung cancer 1995; 13: 99-107.
12. DELBALDO C, SYZ N, MICHIELS S, LE CHEVALIER T, PIGNON JP. Adding a second or third drug to a chemotherapy regimen in patients with advanced non-small cell-lung carcinoma (NSCLC): A meta-analysis of the literature [abstract]. 39th Annual Meeting of the ASCO. May 32-June 3, 2003, Chicago, Illinois. Meeting Proceeding 2003; 22: 623.
13. DEPIERRE A, MILLERON B, MORO-SIBILOT D, CHEVRET S, QUOIX E et al. French Thoracic Cooperative Group. Preoperative chemotherapy folowed by surgery compared with primary surgery in resectable stage I (except T1N0), II, IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20: 247-253.
14. DILLMAN RO, HERNDON J, SEAGREN SL, EATON WL JR, GREEN MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88: 1210-1215.
15. EBERHARDT W, BILDAT S, KORFEE S, STAMATIS G. Preoperative treatment strategies in stage III non-small cell lung cancer. Lung Cancer 2001; 33 Suppl 1: S51-S59.
16. FURUSE K, FUKUOKA M, KAWAHARA M, NISHIKAWA H, TAKADA Y et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesin, and Cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999; 17: 2692-2699.
17. GEORGOULIAS V, PAPADAKIS E, ALEXOPOULOS A, TSIAFAKI X, RAPTI A et al. Greek Oncology Cooperative Group (GOCG) for Lung Cancer. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 1998; 352: 257-263.
18. GIVIO. Diagnosis and first line treatment of patients with lung cancer in Italian general hospitals. Tumori 1989; 75: 163-167.
19. GREENLEE RT, HILL-HARMON MB, MURRA YT, THUN M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36.
20. HAINSWORTH JD, GRAY JR, MORRISSEY LH, KALMAN LA, HON JK, GRECO FA. Long-term follow-up of patients treated with paclitaxel/carboplatin-based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research Network. J Clin Oncol 2002; 20: 2937-2942.
21. JUAN O, ALBERT A, VILLARROYA T, SANCHEZ R, CASAN R et al. Weekly paclitaxel for advanced non-small cell lung cancer patients not suitable for platinum-based therapy. Neoplasma 2003; 50: 204-209.
22. LE CHEVALIER T. Is adjuvant chemotherapy a part of the curative treatment of operable non-small cell lung cancer? Lung Cancer 2003; 41 Suppl 3: S61.
23. LE CHEVALIER T, BRISGAND D, DOUILLARD JY, PUJOL JL, ALBEROLA V et al. Randomized study of vinorelbin and cisplatin versus vindesine and cisplatin versus vindesine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-367.
24. LE CHEVALIER T, BROWN A, NATALE R, SCAGLIOTTI G, VANSTEENKISTE J et al, on behalf of the Gemzar NSCLC Meta-analysis Group. Gemcitabine in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis of survival and progression free survival data [abstract]. Lung Cancer 2003; 41 Suppl 2: S70.
25. LE CHEVALIER T, for the IALT investigators. Results of the randomized International Adjuvant Lung Cancer Trial (IALT): cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (pts) with resected non-small cell lung cancer (NSCLC) [abstract]. 39th Annual Meeting of the ASCO. May 32-June 3,2003, Chicago, Illinois. Meeting Proceeding 2003; 22: 2.
26. LELORIER J, GREGOIRE G, BENHADDAD A, LAPIERRE J, DERDERIAN F. Discrepancies between meta-analyses and subsequent large randomised, controlled trials. N Engl J Med 1997; 337(8): 536-542.
27. LIBERATI A, ANDREANI A, COLOMBO F, CONFALONIERI C, TOGNONI G. Care of cancer patients in thirty-one general hospitals: methodological aspects and general findings. Eur J Cancer Clin Oncol 1983; 19: 179-185.
28. MARINO P, PAMPALLONA S, PREATONI A, CANTONI A, INVERNIZZI F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994; 106: 861-865.
29. MARINO P, PREATONI A, CANTONI A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in Stage IIIa and IIIb NSCLC: A meta-analysis study [abstract]. Chest 1994; 106 Suppl 2: 70S.
30. MCWILLIAMS A. MACAULAY C, GAZDAR AF, LAM S. Innovative molecular and imaging approaches for the detection of lung cancer and its precursor lesions. Oncogene 2002; 21: 6949-6959.
31. MORNEX F. Chemoradiation of stage III NSCLC. Lung Cancer 2003; 41 Suppl 3: S70.
32. NICOLUCCI A, GRILLI R, ALEXANIAN AA, APOLONE G, TORRI V, LIBERATI A. Quality, evolution, and clinical implications of randomised controlled trials on the treatment of lung cancer. A lost opportunity for meta-analysis. JAMA 1989; 262: 2101-2107.
33. NON-SMALL CELL LUNG CANCER COLLABORATIVE GROUP. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Brit Med J 1995; 311: 899-909.
34. PARKIN DJ, PISANI P, FERLAY J. Global cancer statistics. CA Cancer J Clin 1999; 49: 33-64.
35. POMPE-KIRN V, ZAKOTNIK B, ZADNIK V. Cancer patients in Slovenia. Ljubljana: Istitute of Oncology, 2003.
36. RAKOVITCH E, TSAO M, UNG Y, PIGNOL JP, CHEUNG P, CHOW E. Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys 2004; 58: 196-203.
37. ROSELL R, GOMEZ-CODINA J, CAMPS C, JAVIER SANCHEZ J et al. Preresectional chemotherapy in stage IIIA non-samll-cell lung cancer: a 7-year assessment of randomized controlled trial. Lung Cancer 1999; 26: 7-14.
38. ROTH JA, ATKINSON EN, FOSSELLA F, KOMAKI R, BERNADETTE RYAN M et al. Long-term follow-up of patients enrolled in randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21: 1-6.
39. RUBIO I, LOPEZ-VIVANCO, BARCELO J, MUNOZ A, MANE J et al. Preoperative tratment with cisplatine-gemcitabine in locally advanced NSCLC: survival, toxicity and salvage therapy [abstract 1018]. Eur J Cancer 1999; 35 Suppl 4: S256.
40. SAUSE W, KOLESAR P, TAYLOR S IV, JOHNSON D, LIVINGSTON R et al. Final results of phase III trial in regionally advanced unresectable non-small-cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117: 358-364.
41. SCHAAKE-KONING C, VAN DEN BOGAERT W, DALESIO O, FESTEN J, HOOGENHOUT J et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992; 326: 524-530.
42. SHAW GL, GAZDAR AF, PHELPS R, STEINBERG SM, LINNOILA RI et al. Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem 1996; 24 Suppl: 173-185.
43. SCAGLIOTTI GV, DE MARINIS F, RINALDI M, CRINO L, GRIDELLI C et al, Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer: J Clin Oncol 2002; 20: 4285-4291.
44. SCHILLER JH, HARRINGTON D, BELANI CP, LANGER C, SANDLER A et al, Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
45. SLEVIN ML, STUBBS L, PLANT HJ, WILSON P, GREGORY WM et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. Brit Med J 1990; 300: 1458-1460.
46. SONE S, LI F, YANG ZG, HONDA T, MARUYAMA Y et al. Results of three-year mass screening for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer 2001; 84: 25-32.
47. SOUQUET PJ, CHAUVIN F, BOISSEL JP, BERNARD JP. Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer. Lung Cancer 1995; 12 Suppl 1: S147-S154.
48. SPASOVA I, PETERA J, HYTYCH V. The role of neoadjuvant chemotherapy in marginally resectable or unresectable stage III non-small cell lung cancer. Neoplasma 2002; 49: 189-196.
49. STEWARD L, BURDETT S, SOUHAMI R, PARMAR M. Post-operative radiotherapy in completely resected, early-stage, non-small-cell lung cancer: reflections and future directions. Lancet Oncology 2002; 3: 590-591.
50. STEWART LA, PARMAR MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993; 341: 418-422.
51. SULLIVAN FJ, CARMICHAEL J, GLATSTEIN E, MITCHELL LB. Radiation Biology of Lung Cancer. J Cell Biochem 1996; 24 Suppl: 152-159.
52. TRAVIS WD, LUBIN J, RIES L, DEVESA S. United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer 1996; 77: 2464-2470.
53. TRODELLA L, GRANONE P, VALENTE S, VALENTINI V, BALDUCCI M et al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomized trial. Radiother Oncol 2002; 62: 11-19.
54. VAN ZANDWIJK N, SMIT EF, KRAMER GW, SCHRAMEL F, GANS S et al. G. Gemcitabin and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 2000; 18: 2658-2664.
55. VOKES EE, HERNDON JE 2ND, CRAWFORD J, LEOPOLD KA, PERRY MC et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B Study 9431. J Clin Oncol 2002; 20: 4191-4998.
56. WANG M, GU XZ, YIN WB, HUANG GJ, WANG LJ, ZHANG DW. Randomized clinical trial of postoperative irradiation after surgery for non-small cell lung carcinoma. Chin J Radiat Oncol 1994; 3: 39-43.
57. YANG CH, TSAI CM, WANG LS, LEE YC, CHANG CJ et al. Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer. Br J Cancer 2002; 86: 190-195.